Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fate Therapeutics, Inc. - Common Stock (NQ: FATE )

1.610 -0.050 (-3.01%)
Streaming Delayed Price Updated: 9:48 AM EST, Dec 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fate Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Benzinga's Top Ratings Upgrades, Downgrades For July 12, 2022
Upgrades 
Via Benzinga
Expert Ratings for Fate Therapeutics
Within the last quarter, Fate Therapeutics (NASDAQ:FATE) has observed the following analyst ratings: 
Via Benzinga
Recap: Fate Therapeutics Q1 Earnings
Fate Therapeutics (NASDAQ:FATE) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022
Upgrades 
Via Benzinga
7 Small-Cap Stocks to Buy in July 2022
These are the best small-cap stocks to buy for July 2022. ARCH, AVUV, CEIX, COUR, DVAX, FATE, and TENB can make great investments. 
Via InvestorPlace
Will Another Enlivex Innovation Break The Glass Ceiling For Solid Tumor Treatments?
Cell therapy — the use of stem cells and various engineered immune cells to target difficult-to-treat diseases like cancer and autoimmune conditions — has arguably been one of the big breakthroughs in... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
Via Benzinga
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
What 4 Analyst Ratings Have To Say About Fate Therapeutics
Within the last quarter, Fate Therapeutics (NASDAQ:FATE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total... 
Via Benzinga
Fate Therapeutics: Q4 Earnings Insights
Fate Therapeutics (NASDAQ:FATE) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
Fate Therapeutics's Earnings: A Preview
Fate Therapeutics (NASDAQ:FATE) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
Earnings Outlook For Fate Therapeutics
Fate Therapeutics (NASDAQ:FATE) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch
Natural-killer cell therapy is one of the most recent paradigms in cancer treatment, and two prominent companies working on this new technology are Fate Therapeutics Inc (NASDAQ: FATE) and Century... 
Via Benzinga
Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years?
One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With t... 
Via Benzinga
Here's How Much $100 Invested In Fate Therapeutics 5 Years Ago Would Be Worth Today
Fate Therapeutics (NASDAQ:FATE) has outperformed the market over the past 5 years by 64.83% on an annualized basis. Buying $100 In FATE: 5 years ago, an investor could have... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2021
Upgrades B of A Securities upgraded the previous rating for ONE Gas Inc (NYSE: 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Barclays boosted the price target on Sysco Corporation (NYSE: 
Via Benzinga
The Daily Biotech Pulse: Mesoblast, Novartis Sever COVID-19 Treatment Partnerships, Sigilon To Reduce Workforce, ASH Presentations Move Stocks
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Vaccitech To Buy Avidea For $40M Vaccitech plc (NASDAQ: VACC) announced that... 
Via Benzinga
Fate Therapeutics Showcases Interim Data From FT596 Cell Program In Lymphoma
Fate Therapeutics Inc (NASDAQ: FATE) showcased interim Phase 1 data from its FT596 program for patients with relapsed / refractory B-cell lymphoma (BCL) at the... 
Via Benzinga
Hedge Funds Are Selling Vontier Corporation
Vontier Corporation investors should pay attention to a decrease in activity from the world’s largest hedge funds recently. Vontier Corporation was in 31 hedge funds’ portfolios at the end of... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021
Upgrades For CarMax Inc (NYSE: 
Via Benzinga
Cathie Wood Likes Fate Therapeutics, Should You?
The biotech has an interesting pipeline, but it's all early stage products. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021
Upgrades JP Morgan upgraded the previous rating for New Relic Inc (NYSE: 
Via Benzinga
Fate Therapeutics, inc (FATE) Q3 2021 Earnings Call Transcript
FATE earnings call for the period ending October 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
3 Biotech Stocks to Watch Now
Biotech companies develop new medicines, vaccines, or medical devices. They use advanced technologies and medical science to do so. Most biotech stocks trade at low prices and... 
Via Benzinga
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
Recent Poor Results Have Made This Promising Cathie Wood Pick a Bargain
Positive news versus poor clinical trial results may determine the future of Fate Therapeutics. 
Via The Motley Fool
Exposures Product Safety
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.